Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neuroendocrine Tumors 7Sarcoma 3Small Cell Lung Carcinoma 2Neoplasms 2Biliary Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × surufatinib × Clear all
NCT04169672 2023-03-02

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Hutchmed

Phase 2 Completed
248 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡